The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews.
Multiple new biological treatments for Crohn's disease and ulcerative colitis are becoming available. Specifically, vedolizumab and ustekinumab are monoclonal antibodies that target molecular pathways relevant to disease pathogenesis. What can Cochrane reviews tell us about the efficacy, safety, and immunogenicity of these new agents? A Cochrane inflammatory bowel disease group symposium held at the 2015 Digestive Diseases Week annual meeting addressed these questions. This article reviews the data presented at that session.
*Division of Gastroenterology, Department of Medicine, Western University, London, Ontario, Canada; †Robarts Clinical Trials, Inc., Robarts Research Institute, Western University, London, Ontario, Canada; ‡Division of Gastroenterology, Department of Internal Medicine, University Hospital Gasthuisberg, Leuven, Belgium; §Division of Gastroenterology, University of California San Diego, La Jolla, California; and ‖Departments of Medicine and Epidemiology and Statistics, Western University, London, Ontario, Canada.
Reena
R
Khanna
Nilesh
N
Chande
Séverine
S
Vermeire
William J
WJ
Sandborn
Claire E
CE
Parker
Brian G
BG
Feagan
D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D001688:Biological Products / Q000276:immunology / Q000627:therapeutic use; D015815:Cell Adhesion Molecules; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D003226:Congresses as Topic; D003424:Crohn Disease / Q000188:drug therapy*; D019317:Evidence-Based Medicine; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007136:Immunoglobulins; D008214:Lymphocytes / Q000187:drug effects / Q000502:physiology; D060046:Maintenance Chemotherapy; D009088:Mucoproteins / Q000037:antagonists & inhibitors; D012074:Remission Induction; D012196:Review Literature as Topic; D000069549:Ustekinumab / Q000009:adverse effects / Q000627:therapeutic use*
D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D015815:Cell Adhesion Molecules; D005765:Gastrointestinal Agents; D007136:Immunoglobulins; C504265:MADCAM1 protein, human; D009088:Mucoproteins; C543529:vedolizumab; D000069549:Ustekinumab; C559198:etrolizumab